Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.

ABSTRACT:

Background

The early diagnosis of hepatocellular carcinoma (HCC) can greatly improve patients' 5-year survival rate, and the early efficacy assessment is important for oncologists to harness the anti-programmed cell death protein 1 (PD-1) immunotherapy in patients with advanced HCC. The lack of effective predicting biomarkers not only leads to delayed detection of the disease but also results in ineffective immunotherapy and limited clinical survival benefit.

Methods

We exploited the single-cell approach (cytometry by time of flight (CyTOF)) to analyze peripheral blood mononuclear cells from multicohorts of human samples. Immune signatures for different stages of patients with HCC were systematically profiled and statistically compared. Furthermore, the dynamic changes of pe

SUBMITTER: Shi J 

PROVIDER: S-EPMC8804705 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature